Virax Biolabs Group Limited

VRAX

Healthcare|Biotechnology|GB

$0.79

-0.39 (-32.89%)

DCF Value

$14.60

Tangible Book / Share

$18.45

Cash / Share

$16.39

Analyst Consensus

Buy1 analysts

Strong Buy

Buy

Hold

Sell

Strong Sell

Consensus Target

$1.00

Implied Upside

+26.3%

Low Target

$1.00

High Target

$1.00

Price Target Trend

Last Month

—

0 targets

Last Quarter

—

0 targets

Last Year

$1.00

1 target · +26% vs price

All Time

$1.00

1 target · +26% vs price

Rating Trend

Apr 25

1 buy · 0 hold · 0 sell

May 25

1 buy · 0 hold · 0 sell

Jun 25

1 buy · 0 hold · 0 sell

Jan 26

1 buy · 0 hold · 0 sell

Feb 26

1 buy · 0 hold · 0 sell

Mar 26

1 buy · 0 hold · 0 sell

Apr 26

1 buy · 0 hold · 0 sell

May 26

1 buy · 0 hold · 0 sell

Recent Price Targets

Date	Firm	Analyst	Target	Price Then	Source
Jan 9, 2026	H.C. Wainwright		$1.00(+166%)	$0.38	TheFly

Recent Rating Actions

Firm	Action	Rating	Date
HC Wainwright & Co.	maintain	Buy	Jan 9, 2026

Earnings History

Next report: Dec 2, 2026 · EPS est. $-1.75

Report Date	EPS Actual	EPS Est.	Revenue Actual	Revenue Est.
Jul 6, 2026	$-12.64	$-1.75	$12.4K	$12.4K
Nov 1, 2025	$-12.25	$-8.50	$2.0K	$10.0M
Jul 2, 2025	$-19.00	$-8.50	$1.4K	$5.0M
Nov 20, 2024	$-22.25	—	$5.0K	$3.0M
Aug 20, 2024	$-42.75	—	$79.9K	$1.0M
Jan 12, 2024	$-41.00	—	$76.5K	$400.0K
Jun 14, 2023	$-64.50	—	$2.8K	$200.0K
Feb 2, 2023	$-31.00	—	$5.8K	—

News

Virax Biolabs Appoints Three Distributors for ImmuneSelect Research Products in Mainland China

Three new distributor agreements build on initial China sales and extend the Company's distributor-led commercial strategy LONDON, Oct. 29, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that, through its China subsidiary, Shanghai Xitu Consulting Co., Ltd., it has entered into non-exclusive distribution agreements with AmyJet Scientific Inc., Jiangsu Real-Gen Biotechnology Co., Ltd.

Oct 29, 2026prnewswire.com

Virax Biolabs Group Limited (NASDAQ:VRAX) Sees Large Decline in Short Interest

Virax Biolabs Group Limited (NASDAQ: VRAX - Get Free Report) was the target of a large drop in short interest during the month of September. As of September 30th, there was short interest totaling 6,645 shares, a drop of 78.2% from the September 15th total of 30,516 shares. Based on an average daily volume of 30,903

Oct 12, 2026defenseworld.net